Get started
Work

Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates

Year: 2017
Type: article
Abstract: MEFs and GI254023X-treated human cancer cell and tissue lysates, respectively. Additionally, the modified PrAMA simultaneously quantified with significant accuracy ADAM10sa and ADAM17sa in multiple human tumor specimens, and showed the essential characteristics of a robust high throughput multiplex assay that could be broadly used in biomarker studies. Selectively measuring specific enzyme activities, this new clinically applicable assay is potentially superior to the standard protein- and gene-expression assays that do not distinguish active and inactive enzyme forms.
DOI: 10.7150/jca.20779
Authors: Toshie Yoneyama, Michael Gorry, Miles A Miller, Autumn Gaither-Davis, Yan Lin, Marcia L. Moss, Linda G. Griffith, Douglas A. Lauffenburger, Laura P. Stabile, James G. Herman, Nikola L. Vujanovic
Institutions: UPMC Hillman Cancer Center, VA Pittsburgh Healthcare System, Harvard University, Massachusetts General Hospital, Center for Systems Biology, BioZyme (United States), Massachusetts Institute of Technology, University of Pittsburgh
Language: English
Subfield: Cancer Research
Open Access status: gold
Estimated APC paid: $1,337
OpenAlex ID: W2766629977
FWCI: 0.246
Cites: 41
Cited by: 4
Related to: 10